RBM34 Antibody
Description
Introduction to RBM34 Antibody
RBM34 antibody is a polyclonal antibody developed against a synthetic peptide corresponding to amino acids 385–430 of human RBM34 . It is validated for use in Western blot (WB) and reacts with RBM34 in human, mouse, and rat samples . This antibody enables researchers to detect RBM34 expression, which is frequently amplified in cancers such as HCC and linked to poor clinical outcomes .
Applications in Cancer Research
RBM34 antibody has been instrumental in:
-
Diagnostic Studies: Identifying RBM34 overexpression in HCC tissues compared to normal liver samples (AUC = 0.912 in ROC analysis) .
-
Functional Assays: Demonstrating RBM34’s role in promoting HCC cell proliferation, migration, and sorafenib resistance through in vitro and in vivo knockout models .
-
Pathway Analysis: Linking RBM34 to PI3K-AKT pathway activation and FGFR2 expression modulation .
Clinical and Prognostic Insights
| Clinicopathological Feature | Association with High RBM34 Expression | p-Value |
|---|---|---|
| Histologic Grade (G3/G4) | Positive correlation | 0.006 |
| AFP >400 ng/mL | Positive correlation | 0.005 |
| Metastasis (M1 Stage) | Higher expression | 0.629 |
Immune Modulation
RBM34 expression correlates with tumor immune infiltration, including regulatory T cell markers (e.g., FOXP3) and immune checkpoints (e.g., PD-L1) .
Technical Considerations
-
Dilution Optimization: Use 1:500–1:1000 dilution for WB to minimize background noise .
-
Sample Preparation: Validated in cell lysates (Huh7, SK-hep1) and xenograft tumor tissues .
-
Limitations: Not yet validated for immunohistochemistry (IHC) in the provided datasets, though RBM34 protein levels in HCC were confirmed via IHC in independent studies .
